NEW YORK (GenomeWeb News) – The Nordic EMBL Partnership for Molecular Medicine has officially inaugurated the Institute for Molecular Medicine Finland, or FIMM, a joint research institute operated by the University of Helsinki in collaboration with the Hospital District of Helsinki and Uusimaa, or HUS; the National Institute for Health and Welfare; and the VTT Technical Research Centre of Finland.
FIMM is the newest member of the partnership, which includes the Centre for Molecular Medicine Norway, based at the University of Oslo, and the Laboratory for Molecular Infection Medicine Sweden, based at Umeå University.
FIMM employs 150 people in 11 research groups and five technology groups. The research groups study cancer, as well as cardiovascular, neuro-psychiatric and viral diseases. FIMM also carries out translational research designed to explore new diagnostics and treatments, and seeks to promote human health through research on personalized medicine.
In a statement, FIMM said it will work to enhance its global profile through international recruitment, new career paths, and collaborations with industry and healthcare providers.
FIMM Director Olli Kallioniemi said in the statement that the institute's advanced technologies "enable us to investigate molecular mechanisms of disease using genomics and medical systems biology helping us to bridge from discovery to medical applications."
Initiated in 2007, the Nordic EMBL Partnership for Molecular Medicine is dedicated to research in molecular medicine, investigation of the molecular basis of disease and the discovery of new treatments.